13D Filing: Osmium Partners and Diversicare Healthcare Services Inc. (DVCR)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549

SCHEDULE 13D

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

RULE 13d-2(a)

(Amendment No. )*

DIVERSICARE HEALTHCARE SERVICES,
INC.
(Name of Issuer)

Common Stock, par value $0.10
(Title
of Class of Securities)

255104101
(CUSIP Number)

Osmium Partners, LLC
300 Drakes Landing Road,
Suite 172
Greenbrae, CA 94904
Attention: John H. Lewis

Telephone: (415) 785-4044
(Name, Address and
Telephone Number of Person Authorized to Receive Notices and
Communications)

September 8, 2017
(Date of Event Which
Requires Filing of this Statement)

If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g),
check the following box [X].

Note. Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits.
See Rule 13d-7(b) for other parties to whom copies are to be sent.

    The information required on the remainder of this cover
page shall not be deemed to be filed for the purpose of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes.)

CUSIP No. 255104101

CUSIP No. 255104101

CUSIP No. 255104101

CUSIP No. 255104101

CUSIP No. 255104101

EXPLANATORY NOTE

This Statement on Schedule 13D reflects, that as of September
8, 2017, the Reporting Persons are disclosing their beneficial ownership in
Diversicare Healthcare Services, Inc. (Diversicare or the Issuer) on
Schedule 13D instead of Schedule 13G. The Reporting Persons previously disclosed
their beneficial ownership in the Issuer inn Amendment No. 2 to Schedule 13G as
filed with the Securities and Exchange Commission (the SEC) on February 14,
2017.

ITEM 1. Security and Issuer.

The name of the issuer is Diversicare Healthcare Services, Inc.
(the Issuer). The principal executive office of the Issuer is located at 1621
Galleria Boulevard, Brentwood, TN 37027-2926.

ITEM 2. Identity and Background.

(a)-(c) and (f) The names of the persons jointly filing this
statement on Schedule 13D (the Reporting Persons) are: (1) Osmium Capital, LP,
a Delaware limited partnership (Fund I); (2) Osmium Capital II, LP, a Delaware
limited partnership (Fund II); (3) Osmium Spartan, LP, a Delaware limited
partnership (Fund III, and collectively with Fund I and Fund II, the Funds);
(4) Osmium Partners, LLC, a Delaware limited liability company (Osmium
Partners); and (5) John H. Lewis, a United States Citizen (Lewis). Osmium
Partners serves as the general partner of Fund I, Fund II and Fund III. Mr.
Lewis is the controlling member of Osmium Partners.

The principal business of each of Fund I, Fund II and Fund III
is that of a private investment vehicle engaged in investing and trading in a
wide variety of securities and financial instruments for its own account. The
principal business of Osmium Partners is providing investment management
services and serving as the general partner of Fund I, Fund II and Fund III. Mr.
Lewis principal occupation is serving as the Managing Member of Osmium
Partners.

(d)(e) During the last five years, none of the Reporting
Persons have been (a) convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors) or (b) a party to a civil proceeding of a
judicial or administrative body of competent jurisdiction and as a result of
such proceeding was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal
or state securities laws or finding any violation with respect to such laws.

ITEM 3. Source and Amount of Funds or Other Consideration

The source and amount of funds (excluding commissions) used by
the Funds in making their purchase of the shares of Common Stock owned by each
of them in the aggregate was $5,271,595.33 from working capital.

One or more of the Reporting Persons effect purchases of
securities through margin accounts which may extend margin credit to the
Reporting Persons as and when required to open or carry positions in the margin
accounts, subject to applicable federal margin regulations, stock exchange rules
and brokers credit policies. In such instances, the positions held in the
margin accounts are pledged as collateral security for the repayment of debit
balances in the accounts.

ITEM 4. Purpose of Transaction

The Reporting Persons purchased the Common Stock based on the
belief that such securities, when purchased, were undervalued and represented an
attractive investment opportunity. Although no Reporting Person has any specific
plan or proposal to acquire or dispose of the Common Stock, consistent with its
investment purpose, each Reporting Person at any time and from time to time may
acquire additional Common Stock or dispose of any or all of its Common Stock
depending upon an ongoing evaluation of the investment in the Common Stock,
prevailing market conditions, other investment opportunities, liquidity
requirements of the Reporting Persons, and/or other investment considerations.
The purpose of the acquisitions of the Common Stock was for investment, and the
acquisitions of the Common Stock were made in the ordinary course of business
and were not made for the purpose of acquiring control of the Issuer.

Consistent with their investment purpose, the Reporting Persons
have engaged in communications with the board of directors of the Issuer to urge
the board to substantially increase the current dividend payout as the Reporting
Persons believe that the Issuers Common Stock is significantly undervalued. In
connection with our communications with the board of directors of the Issuer we have issued a press release, dated as of
September 8, 2017, a copy of which is attached hereto as Exhibit 2 and is
incorporated herein by reference.

Except as disclosed above, none of the Reporting Persons has
any other plans or proposals which relate to, or would result in, any of the
matters referred to in paragraphs (a) through (j), inclusive, of the
instructions to Item 4 of Schedule 13D. The Reporting Persons may, at any time
and from time to time, review or reconsider their position and/or change their
purpose and/or formulate plans or proposals with respect thereto.

ITEM 5. Interest in Securities of the Issuer

Each Reporting Person disclaims beneficial ownership with
respect to any shares of Common Stock other than the shares owned directly and
of record by such Reporting Person.

The percentages set forth in this response are based on the
6,458,836 shares of Common Stock outstanding as of July 28, 2017, as reported by
the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30,
2017 as filed with the SEC on August 3, 2017.

(b) Osmium Partners and Mr. Lewis may be deemed to share with
Fund I, Fund II and Fund III (and not with any third party) the power to vote or
direct the vote of and to dispose or direct the disposition of the 356,106
shares of Common Stock, 172,993 shares of Common Stock and 113,804 shares of
Common Stock reported herein, respectively.

(c) The following Reporting Persons engaged in the following
transactions with respect to the Issuers Common Stock during the 60 days
preceding September 8, 2017 and the 60 days preceding the date of this
filing:

Osmium Capital, LP

Osmium Capital II, LP

Osmium Spartan, LP

Other than the foregoing, no transactions in the Common Stock
have been effected by the Reporting Persons in the 60 days preceding September
8, 2017 and the 60 days preceding the date of this filing.

ITEM 6. Contracts, Arrangements, Understandings or
Relationships With Respect to Securities of the Issuer.

Not applicable.

ITEM 7. Material to be Filed as Exhibits.

SIGNATURE

     After reasonable inquiry and to
the best of my knowledge and belief, the undersigned certify that the
information set forth in this statement is true, complete and correct.

Dated: September 11, 2017

John H. Lewis
Osmium Partners, LLC

Osmium Capital, LP
Osmium Capital II, LP
Osmium
Spartan, LP

By:   /s/ John H.
Lewis

John H. Lewis, for himself and as
Managing Member of Osmium

Partners, LLC, for itself and as
General Partner of Osmium
Capital,
LP, Osmium Capital II,
LP and Osmium Spartan, LP

EXHIBIT INDEX